October 06, 2025

Can Nicotinamide Reduce the Risk of Skin Cancer Development?

A retrospective study aimed to determine the clinical efficacy of nicotinamide supplementation for skin cancer prevention in the general population and among solid organ transplant recipients.

The ASCO Post

October 02, 2025

RP1 Oncolytic Therapy Provides New Hope for Patients Whose Melanoma Resists Conventional Immunotherapy

About half of all patients with advanced melanoma face a poor prognosis because their cancer doesn’t respond to immunotherapy — but results of a recent clinical trial show that an unusual treatment strategy could change that.

Roswell Park Comprehensive Cancer Center

January 01, 0001

A New Immunotherapy for Melanoma?

New research reveals ipilimumab could enhance survival in metastatic melanoma patients, challenging longstanding treatment limitations.

JADPRO

January 01, 2024

Streamlining Layered Composite Veneer Procedures

Discover how transparent matrices are revolutionizing dental practice for efficient, esthetic outcomes. Sandra Hulac, DDS, shares insights on incorporating direct composite veneers with reduced chairside time, delivering exceptional esthetics.

Inside Dentistry

June 01, 2013

Conservative Preparation Guidelines for CAD/CAM Restorations

Chairside CEREC® eliminates the need for conventional impression taking, temporary restorations, and multiple appointments. CAD/CAM scanning and design enables preparations within enamel and an ideal, conservative bonded restoration.

Compendium

June 01, 2023

Check the Lids for Demodex Blepharitis

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management

May 01, 2023

INNOVATION

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Ophthalmology Management

May 19, 2021

Immunotherapy Combination Shows Benefit for Patients with Advanced Melanoma, Phase 3 Trial Shows

A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study. Findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021, and are included in the ASCO press program.

Dana-Farber

September 17, 2025

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could...

The ASCO Post